New hope for glioblastoma? drug combo trial launches
NCT ID NCT07326566
First seen Jan 09, 2026 · Last updated Jun 23, 2026 · Updated 27 times
Summary
This phase 2 trial tests whether adding silevertinib, an oral drug that targets a specific protein (EGFR), to standard chemotherapy (temozolomide) helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The study includes 162 participants whose tumors have certain genetic markers (unmethylated MGMT and EGFRvIII). The goal is to see if the combination improves how long people live without their cancer getting worse compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health
RECRUITINGSummit, New Jersey, 07901, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Highlands Oncology Group
RECRUITINGSpringdale, Arkansas, 72762, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
John Theurer Cancer Center at Hackensack University Medical Center
RECRUITINGHackensack, New Jersey, 07601, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Miami Cancer Institute
RECRUITINGMiami, Florida, 33176, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10461, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwell Health Center for Advanced Medicine - Brain Tumor Center
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prisma Health
RECRUITINGGreenville, South Carolina, 29605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine Siteman Cancer Center
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
silevertinib (also called BDTX-1535) combined with temozolomide (Temodar)
What this could lead to
If it works, this combination could slow or stop glioblastoma growth better than current standard treatment, potentially extending life without progression.
What could go wrong
This is a phase 2 trial with only 162 people, so results are preliminary. The drug may not improve outcomes and could cause side effects like those from other EGFR inhibitors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.